Somatic copy number abnormalities and mutations in PI3K/AKT/mTOR pathway have prognostic significance for overall survival in platinum treated locally advanced or metastatic urothelial tumors

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Bellmunt, Joaquim ^a   Werner, Lillian ^b   Leow, Jeffrey J ^a   Mullane, Stephanie A ^a   Fay, André P ^a   Riester, Markus ^b   Van Hummelen, Paul ^b   Taplin, Mary Ellen ^a   Choueiri, Toni K ^a   Van Allen, Eliezer ^a   Rosenberg, Jonathan ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATINUM DERIVATIVE; PROTEIN KINASE; PROTEIN P53; RAF PROTEIN; RAS PROTEIN; RNA; WNT PROTEIN; ANTINEOPLASTIC AGENT; MTOR PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PLATINUM; PROTEIN KINASE B; TARGET OF RAPAMYCIN KINASE;

ADVANCED CANCER; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COPY NUMBER VARIATION; CTNNB1 GENE; DNA EXTRACTION; ERBB2 GENE; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; METASTASIS; OVERALL SURVIVAL; PIK3CA GENE; RNA EXTRACTION; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TP53 GENE; UROGENITAL TRACT TUMOR; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; GENE DOSAGE; GENETICS; MALE; MORTALITY; MULTICENTER STUDY; SURVIVAL RATE; UROLOGIC NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; GENE DOSAGE; HUMANS; MALE; PHOSPHATIDYLINOSITOL 3-KINASES; PLATINUM; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SURVIVAL RATE; TOR SERINE-THREONINE KINASES; UROLOGIC NEOPLASMS;

EID: 84931267399     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0124711     Document Type: Article

References (35)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64(1):9-29.
2. Burger M, Oosterlinck W, Konety B, Chang S, Gudjonsson S, Pruthi R, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder. European urology. 2013; 63(1):36-44. doi: 10.1016/j.eururo.2012.08.061 PMID: 22981672
3. Advanced Bladder Cancer Meta-analysis C. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. European urology. 2005; 48(2):202-205; discussion 205-206. PMID: 15939524
4. Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PloS one. 2010; 5(11):e13821. doi: 10.1371/journal.pone.0013821 PMID: 21072204
5. Juanpere N, Agell L, Lorenzo M, de Muga S, Lopez-Vilaro L, Murillo R, et al. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer. Human pathology. 2012; 43(10):1573-1582. doi: 10.1016/j.humpath.2011.10.026 PMID: 22417847
6. Korkolopoulou P, Levidou G, Trigka EA, Prekete N, Karlou M, Thymara I, et al. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma. BJU international. 2012; 110(11 Pt C):E1237-1248.
7. The Cancer Genome Atlas Research N. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014.
8. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome biology. 2011; 12(4):R41. doi: 10.1186/gb-2011-12-4-r41 PMID: 21527027
9. Millis SZ, Bryant D, Basu G, Bender R, Vranic S, Gatalica Z, et al. Molecular Profiling of Infiltrating Urothelial Carcinoma of Bladder and Nonbladder Origin. Clinical genitourinary cancer. 2014.
10. Ross JS, Wang K, Al-Rohil RN, Nazeer T, Sheehan CE, Otto GA, et al. Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2014; 27(2): 271-280.
11. Bambury RM, Rosenberg JE. Actionable mutations in muscle-invasive bladder cancer. Current opinion in urology. 2013; 23(5):472-478. doi: 10.1097/MOU.0b013e328363a3cd PMID: 23907505
12. Polivka J, Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther. 2013.
13. Ching CB, Hansel DE. Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway. Lab Invest. 2010; 90(10):1406-1414. doi: 10.1038/labinvest.2010.133 PMID: 20661228
14. Platt FM, Hurst CD, Taylor CF, Gregory WM, Harnden P, Knowles MA. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res. 2009; 15(19):6008-6017. doi: 10.1158/1078-0432.CCR-09-0898 PMID: 19789314
15. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98(18):10314-10319. PMID: 11504908
16. Houede N, Pourquier P. Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: Its potential use in the treatment of bladder cancers. Pharmacology & therapeutics. 2014.
17. Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, et al. PIK3CA mutation associates with improved outcome in breast cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15(16):5049-5059. doi: 10.1158/1078-0432.CCR-09-0632 PMID: 19671852
18. Shigaki H, Baba Y, Watanabe M, Murata A, Ishimoto T, Iwagami S, et al. PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013; 19(9):2451-2459. doi: 10.1158/1078-0432.CCR-12-3559 PMID: 23532889
19. Kim PH, Cha EK, Sfakianos JP, Iyer G, Zabor EC, Scott SN, et al. Genomic Predictors of Survival in Patients with High-grade Urothelial Carcinoma of the Bladder. European urology. 2014.
20. Lae M, Couturier J, Oudard S, Radvanyi F, Beuzeboc P, Vieillefond A. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2010; 21(4):815-819. doi: 10.1093/annonc/mdp488 PMID: 19889613
21. Fleischmann A, Rotzer D, Seiler R, Studer UE, Thalmann GN. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur Urol. 2011; 60(2):350-357.
22. Galsky MD, Von Hoff DD, Neubauer M, Anderson T, Fleming M, Nagarwala Y, et al. Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Invest New Drugs. 2012; 30(2):695-701. doi: 10.1007/s10637-010-9541-0 PMID: 20857170
23. Memon AA, Sorensen BS, Meldgaard P, Fokdal L, Thykjaer T, Nexo E. The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients. Br J Cancer. 2006; 94(11):1703-1709. PMID: 16685269
24. van Rhijn BW, van der Kwast TH, Liu L, Fleshner NE, Bostrom PJ, Vis AN, et al. The FGFR3 mutation is related to favorable pT1 bladder cancer. J Urol. 2012; 187(1):310-314. doi: 10.1016/j.juro.2011.09.008 PMID: 22099989
25. Lamont FR, Tomlinson DC, Cooper PA, Shnyder SD, Chester JD, Knowles MA. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer. 2011; 104(1):75-82. doi: 10.1038/sj.bjc.6606016 PMID: 21119661
26. Milowsky MI, Dittrich C, Martinez ID, Jagdev S, Millard FE, Sweeney C, et al. Final results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3. Journal of Clinical Oncology. (supplementary abstract) 2013.
27. Williams SV, Hurst CD, Knowles MA. Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet. 2013; 22(4):795-803. doi: 10.1093/hmg/dds486 PMID: 23175443
28. Rastislav B,Dienstmann R, Adamo B, Gazzah G, Infante JR, Zhong B,et al;. Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors. J Clin Oncol 32:5s, 2014 (suppl; abstr 2501). 2014.
29. Sequist LV Cassier P, Varga A, Tabernero J, Schellens JH, Delord JP, et al. Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors. 2014 AACR Annual Meeting. Abstract CT326. Presented April 8, 2014. 2014.
30. Iyer G, Al-Ahmadie H, Schultz N, Hanrahan AJ, Ostrovnaya I, Balar AV, et al. Prevalence and cooccurrence of actionable genomic alterations in high-grade bladder cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013; 31(25):3133-3140.
31. Cairns P, Proctor AJ, Knowles MA. Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma. Oncogene. 1991; 6(12):2305-2309. PMID: 1766677
32. Ahmad I, Singh LB, Foth M, Morris CA, Taketo MM, Wu XR, et al. K-Ras and beta-catenin mutations cooperate with Fgfr3 mutations in mice to promote tumorigenesis in the skin and lung, but not in the bladder. Disease models & mechanisms. 2011; 4(4):548-555.
33. MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, et al. Profiling critical cancer gene mutations in clinical tumor samples. PloS one. 2009; 4(11):e7887. doi: 10.1371/journal.pone.0007887 PMID: 19924296
34. Matulonis UA, Hirsch M, Palescandolo E, Kim E, Liu K, van Hummelen P. et al. High throughput interrogation of somatic mutations in high grade serous cancer of the ovary. PloS one. 2011; 6(9):e24433. doi: 10.1371/journal.pone.0024433 PMID: 21931712
35. Gui Y, Guo G, Huang Y, Hu X, Tang A, Gao S. et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet. 2011; 43(9):875-878. doi: 10.1038/ng.907 PMID: 21822268